News Articles and Montana BioScience Alliance Newsletters
The four-year grant will enable MSU and its partners from across Montana to deliver quality medical, dental and behavioral health care to kids in rural and underserved areas while providing exceptional educational opportunities for MSU students.
In making the announcement, MSU President Waded Cruzado said “During the pandemic, Dr. Carter helped lead a group of MSU faculty, students and staff in significantly increasing Montana’s COVID-19 testing capacity during the pandemic. He oversaw the MSU research enterprise, the state’s largest, when it set records in expenditures in 2020, 2021 and set it on track to set another record this year.”
Montana State University Billings’ Suzette Nynas, associate professor and department chair for the health and human performance department, was recently inducted into the Montana Athletic Trainers’ Association Hall of Fame.
Since 2004, approximately 1,200 clinical trials have been conducted in Montana. That’s just one of the facts in the report “Research in Your Backyard: Developing Cures, Creating Jobs – Pharmaceutical Clinical Trials in Montana.” The report was the subject of a recent seminar in Billings sponsored by the Montana BioScience Alliance and the Pharmaceutical Research and Manufacturers of America (PhRMA).
Montana Tech was recently awarded a five-year, $24 million grant from the Army Research Laboratory to develop a program called “Materials Technology for Rare Earth Elements Processing.” This program, which responds to a critical national need to develop a supply chain for rare earth elements, is a multidisciplinary effort that will use Montana as a model for locating rare earth elements in primary and secondary sources.
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
View the Spring 2024 Newsletter Newsletter now!
View the Winter II 2024 Newsletter now!